1. Medicines
  2. Medicines-Respiratory
  3. ULTIBRO® BREEZHALER® (indacaterol maleate/glycopyrronium bromide inhalation powder)

ULTIBRO® BREEZHALER® (indacaterol maleate/glycopyrronium bromide inhalation powder)

Ultibro® Breezhaler®

INHALER TECHNIQUE VIDEO FOR ULTIBRO® BREEZHALER®

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

See for yourself how the Ultibro® Breezhaler® device works

See how to administer Ultibro® Breezhaler® correctly.

 

Inhaler Technique for Ultibro Breezhaler

Download Instructions for Use

ie402287-ultibro_instructionsbookmarks

ie402287-ultibro_instructionsbookmarks

 
Rate this content: 
No votes yet
IE402214 | January 2024
Respiratory
Medicines
ULTIBRO® BREEZHALER® SPC
Print
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.